Ken Griffin Acadia Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$15.14 - $19.14 $146,858 - $185,658	-9,700 Reduced 10.81%	80,000 $1.23 Million
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $122,808 - $154,728	8,400 Added 10.33%	89,700 $1.46 Million
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $5,337 - $9,258	300 Added 0.37%	81,300 $1.5 Million
Q4 2023 Feb 14, 2024	SELL	$20.78 - $31.77 $16,624 - $25,416	-800 Reduced 0.98%	81,000 $2.54 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $1.08 Million - $1.74 Million	51,900 Added 173.58%	81,800 $1.7 Million
Q2 2023 Aug 14, 2023	SELL	$17.8 - $25.65 $115,700 - $166,725	-6,500 Reduced 17.86%	29,900 $716,000
Q1 2023 May 15, 2023	SELL	$16.32 - $20.92 $1.41 Million - $1.8 Million	-86,200 Reduced 70.31%	36,400 $685,000
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $362,100 - $475,065	-25,500 Reduced 17.22%	122,600 $1.95 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $4.36 Million - $5.65 Million	-309,100 Reduced 67.61%	148,100 $2.42 Million

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.63B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.